Sanofi completes Dynavax deal: what it means for DVAX stock

Published on 10/01/2026 at 16:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The transaction valued Dynavax at USD 2.20 billion on February 10, 2026. DVAX stock showed USD 15.50 on February 11, 2026, the tender price.

DVAX, US2681581009, Illustration mit AI erstellt.

Sanofi completed its acquisition of Dynavax Technologies Corporation (ISIN US2681581009) on February 10, 2026, after the tender offer expired with all conditions met, according to Simplify Jobs. For DVAX investors, the transaction changed the security from a publicly traded vaccine company into an indirect Sanofi subsidiary.

Sanofi paid USD 2.20 billion

According to Multiples.vc on September 19, 2026, Sanofi agreed to pay USD 15.50 per Dynavax share in cash, giving the deal an equity value of USD 2.20 billion. The same source says the tender offer expired on February 9, 2026, one day before the merger was completed.

The consideration represented a 39.00 percent premium to Dynavax's December 23, 2025 closing price, while the source also reported a 46.00 percent premium to the three-month volume-weighted average price. Those comparisons explain why the transaction price, rather than a fresh operating update, is the key reference for former DVAX holders.

HEPLISAV-B anchors the deal

Dynavax's commercial asset was HEPLISAV-B, a two-dose adult hepatitis B vaccine. Multiples.vc reported USD 95.00 million in HEPLISAV-B sales in the third quarter of 2025 and USD 315.00 million of revenue for December 2025. The product's two-dose schedule and Dynavax's vaccine pipeline gave Sanofi a commercial asset alongside earlier-stage development projects.

Sanofi's acquisition added hepatitis B and shingles-related assets to its vaccine portfolio, as described in the February 10, 2026 announcement reproduced by Simplify Jobs. The strategic logic is therefore tied to product distribution and pipeline integration, not to a new standalone Dynavax earnings cycle.

DVAX becomes a historical quote

A structured Nasdaq quote dated February 11, 2026 showed DVAX at USD 15.50, matching the tender price, with market capitalization of USD 1.8 billion. A September 19, 2026 profile from Multiples.vc described Dynavax as no longer listed after Sanofi's acquisition. The practical takeaway is that the former DVAX quote is a transaction reference, while HEPLISAV-B and the pipeline now sit within Sanofi.